Ignite Creation Date:
2025-12-25 @ 12:56 AM
Ignite Modification Date:
2026-01-24 @ 9:30 PM
Study NCT ID:
NCT02256267
Status:
COMPLETED
Last Update Posted:
2019-01-07
First Post:
2014-10-01
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
A Study of LY2835219 in Healthy Participants
Sponsor:
Eli Lilly and Company
Organization:
Study Overview
Official Title:
Effects of CYP3A Induction by Rifampin on the Pharmacokinetics of LY2835219 and Its Metabolites in Healthy Subjects
Status:
COMPLETED
Status Verified Date:
2018-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
True
If Expanded Access, NCT#:
NCT03763604
Has Expanded Access, NCT# Status:
APPROVED_FOR_MARKETING
Acronym:
None
Brief Summary:
The aim of this two-period study is to compare how much of the study drug gets into the blood stream when it is given as a single oral dose and when it is given as a single oral dose in combination with rifampin (a Food and Drug Administration \[FDA\] approved antibiotic that is used to treat tuberculosis, a bacterial infection that mainly affects the lungs, and other infections). Each participant will complete both study periods.
The study will last about 34 days. Screening is required within 28 days before study drug is given.
The study will last about 34 days. Screening is required within 28 days before study drug is given.
Detailed Description:
None
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
Secondary ID Infos
| Secondary ID | Type | Domain | Link | View |
|---|---|---|---|---|
| I3Y-MC-JPBF | OTHER | Eli Lilly and Company | View |